NewsUrban Co-Op seminarBy John Keogh – July 11, 2014 489 Facebook Print THE Limerick Community Grocery urban co-op, in conjunction with the Park Slope Food Co-op in Brooklyn USA, is hosting an urban cooperative seminar and workshop in Limerick City of Culture HQ this Saturday, July 12 from 10.30am to 5pm.The seminar will discuss the most appropriate urban cooperative model for Limerick.Sign up for the weekly Limerick Post newsletter Sign Up The Limerick Community Grocery was set up in 2013 to provide wholesome food at affordable prices in an open, transparent and co-operative environment.Membership is open to the public and is based on one member one vote.The seminar will also explore Limerick Community Grocerys’ commitment to generating livelihoods through urban agriculture and community gardening initiatives.Attendance at the seminar and workshops is free but prior registration is essential.Register at: www.eventbrite.ie/o/limerick-community-grocery-ltd-6773844299 WhatsApp Advertisement TAGSLimerick co-op Email Linkedin Twitter Previous articleLimerick bucks the trend with increased unemploymentNext articleWriters on the lookout for Limerick’s oldest lady John Keoghhttp://www.limerickpost.ie
“VaxInnate’s M2e universal flu vaccine candidate has passed a critical initial test,” David Taylor, MD, the company’s chief medical officer, said in the news release. “We’re encouraged by these data, which demonstrate that the vaccine is safe and elicits potent immune responses at doses below a microgram [mcg] of vaccine antigen, and does so without the use of conventional adjuvants.” The vaccine, made by VaxInnate Inc., Cranbury, N.J., targets the M2 protein of influenza A viruses, a surface protein that differs little among different strains of type A. Existing flu vaccines target hemagglutinin (HA), a flu surface protein that often mutates, making it necessary to change the vaccine each year to cover the predominant strains in circulation. A vaccine targeting a protein found in all or most flu strains could reduce or eliminate the need to change the vaccine each year. “Should M2e be shown to be protective for influenza A, it’s possible that other universal antigens could be developed for influenza B,” Taylor said in an e-mailed statement. “In the developing world, where influenza vaccine is not available, M2e could be a cost-effective way to provide influenza A coverage. He also commented that VaxInnate is developing seasonal flu vaccines in which its recombinant-bacteria technology is used to make both the A and B components. A vaccine targeting a Solomon Islands strain of H1N1 is currently in clinical testing, and a type B vaccine may become available next year, he said. The two lowest doses were safe and well-tolerated in all the volunteers; they yielded an immune response in 18 of 24 volunteers after the first dose and in 23 of 24 after two doses, VaxInnate said. However, the two highest doses “were associated with the presence of flu-like symptoms in some of the subjects.” Nov 11, 2008 (CIDRAP News) – A vaccine designed to offer protection against many strains of influenza viruses appeared safe in low doses and triggered a satisfactory immune response in a phase 1 clinical trial, the vaccine’s developer announced recently. Plans for targeting type BThe M2e vaccine targets influenza A but not influenza B, the other major type. Type A viruses generally cause more severe illness than type B. Seasonal flu vaccines normally target two type A subtypes—H1N1 and H3N2—and one type B strain, all of which typically circulate each season. “Given the strength of the antibody responses and the absence of significant adverse reactions at the two lowest doses (0.3 and 1.0 mcg), VaxInnate intends to continue development and clinical evaluation of the vaccine candidate at doses of 1.0 mcg and less,” the company said. Flagellin interacts with the immune system’s toll-like receptors, which serve in human immune cells as sentries to detect pathogens and mount a general defense, according to VaxInnate. This initial defense stimulates an adaptive immune response that includes production of pathogen-specific antibodies, the company said. In the trial, 60 healthy volunteers between the ages of 18 and 49 received one of the four doses or a placebo in two injections 28 days apart, the company reported. Safety was assessed 1 and 7 days after immunization, and immune response was examined 7, 14, and 28 days after each dose. Seroconversion was defined as a serum IgG and anti-M2e antibody value of at least 0.174 mcg per milliliter and a fourfold increase in antibody titer. Christine Turley, MD, primary investigator in the study, said in the release that the results for the two lowest doses “suggest that the M2e vaccine candidate could be a promising and much-needed new option for prevention or attenuation of influenza A disease.” She is director of clinical trials and clinical research in the Sealy Center for Vaccine Development, University of Texas Medical Branch (UTMB), Galveston. Fewest events at lowest dosesThe phase 1 trial was a double-blind study designed to test the safety and immunogenicity of four different doses of the vaccine: 0.3, 1, 3, and 10 mcg. It was conducted in Galveston, Tex., and Lenexa, Kan. See also: “The notion of a universal influenza vaccine or any kind of influenza vaccine that reduces the need for annual vaccination or provides better or more reliable protection against influenza viruses—that will be very useful to us,” she said. “Until a vaccine goes all the way through phase 3 clinical trials and we have good evidence about actual protection, the verdict is out. But certainly there are a number of kinds of vaccines in development, such as this one, that are exciting with regard to the prospect of a more universal kind of vaccine.” “VaxInnate is working to develop a second-generation universal vaccine that has M2e and another conserved antigen that will address influenza B strains, as well as influenza A strains. Efficacious universal vaccines for influenza that cover both A and B strains could potentially replace the more standard HA vaccine in some markets and market segments, even in the developed world.” While acknowledging that the M2e vaccine would not cover type B viruses, VaxInnate’s Taylor told CIDRAP News that the company also hopes to develop a second-generation universal vaccine that would target both A and B. Meanwhile, he suggested possible uses for the M2e vaccine by itself, assuming it is successful. Nichol said the measures of immune response used by VaxInnate are reasonable and generally correlate with actual protection, but do not guarantee it. “It’s encouraging but not definitive until we see the clinical protection data,” she said. ‘Encouraging but not definitive’Dr. Kristin Nichol, an experienced flu immunization researcher who was not involved with the study, described VaxInnate’s results as promising but advised a wait-and-see attitude. She is associate chief of staff for research at the Minneapolis VA Medical Center. Taylor also said that in countries where conventional seasonal flu vaccines are available, the M2e vaccine could be used in combination with them to provide increased protection in case the strains in the seasonal vaccine don’t match well with circulating strains. The vaccine consists of the ectodomain of the M2 protein, fused to flagellin, a bacterial protein. The company uses recombinant bacteria to produce the vaccine, a technique that the company says is faster than conventional egg-based production or cell-culture production. The Bill and Melinda Gates Foundation supported the M2e vaccine trial with a $9.5 million grant to UTMB to improve control of flu in the developing world, the company said. The company reported the results in an Oct 26 press release and at the Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America (ICAAC/IDSA) meeting, held Oct 24-28 in Washington, DC. Oct 26 VaxInnate press releasehttp://www.vaxinnate.com/pages/pressreleases/20081026_001.html
INDIANOLA —- Democratic presidential candidate Kamala Harris spent the Thanksgiving holiday in Iowa, including an event Sunday morning in Indianola that attracted about 60 people.“This is what I’m seeing all over the state, which is people who could be doing so many other things with their time coming out to have these conversations,” Harris said.She spoke later Sunday to about 60 people in Knoxville. And Harris dismissed the premise of a New York Times story which cited current and former campaign aides questioning the conduct of her campaign.“I am campaigning hard here in Iowa because I do see the enthusiasm,” Harris said. “When I’m in living rooms, when I am cooking with Iowan families, when I am spending time just walking through a coffee shop.”Harris says she’s lining up support from Iowans who are not necessarily on the radar as likely caucus-goers.